Immutep (ASX:IMM) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


What is Immutep Tariff Resilience Score?

Immutep ASX:IMM +4.17% Tariff Resilience Score is 6 as of Jun. 29, 2026. The stock has 1 warning sign investors should review. Among 1,375 Biotechnology companies, Immutep ranks better than 76% on this metric.

Immutep has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Immutep has Immutep, a biotech firm, has limited direct tariff exposure but relies on global supply chains. The company can leverage alternative suppliers and has some pricing power. Historical impacts have been minimal, with industry-specific protections.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Immutep might have Average Resilient.

Immutep  (ASX:IMM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Immutep Tariff Resilience Score Related Terms

ASX:IMM vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Immutep's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Immutep's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Immutep (ASX:IMM) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Immutep ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Immutep's Tariff Resilience Score too high?
Immutep's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Immutep's value of 6 is 50% above this industry median. Based on the distribution chart, Immutep ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Immutep's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #330 out of 1375 companies for Tariff Resilience Score. This places Immutep in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Immutep's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Immutep (ASX:IMM), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.